The American Cancer Society’s November 12, 2026 guideline now recommends PSA screening every two years for average-risk men aged 50 to 69, and every year from age 45 for Black men and men with a strong family history. An estimated 333,830 US men will be diagnosed with prostate cancer in 2026, and 36,320 will die from it.
Prostate Cancer Screening in US 2026 – Introduction
Prostate cancer screening in US 2026 changed on November 12, when the American Cancer Society (ACS) published its first direct screening schedule since 2010. The old advice told most men to talk with a doctor and decide. The new advice says to test, on a set timetable, with the PSA blood test. Federal advisers have not changed their position, so men now hear two different messages.
This report lays out the new PSA guidelines, the age groups they cover, the high-risk men who should start earlier, and the national numbers behind them. It also shows how many men actually get tested. This report is general information, not medical advice. Men should talk with a doctor about their own risk.
Interesting Facts About Prostate Cancer Screening in US 2026
Estimated US Prostate Cancer, 2026 (1 block = 10,000)
New cases | █████████████████████████████████ 333,830
Deaths | ███▌ 36,320
| Fact | 2026 Data |
|---|---|
| New guideline released | November 12, 2026 |
| Estimated new cases | 333,830 |
| Estimated deaths | 36,320 |
| Average-risk screening | Every 2 years, ages 50-69 |
| High-risk screening | Every year, ages 45-69 |
| Elevated PSA threshold | 3.0 ng/mL (ages 45-69) |
| Lifetime risk | About 1 in 8 men |
| Men aged 55-69 tested in past year (2023) | 38.0% |
Source: American Cancer Society; CA: A Cancer Journal for Clinicians; National Cancer Institute, Cancer Trends Progress Report.
The table shows a common cancer with a high survival rate and a large screening gap. ACS estimates 333,830 new cases and 36,320 deaths for 2026. Roughly 1 in 8 men will be diagnosed in their lifetime. Prostate cancer is the second leading cause of cancer death in American men.
Testing is still uneven. About 38.0% of men aged 55 to 69 had a PSA test in the past year, according to 2023 national survey data. The new schedule asks average-risk men to test every two years, so the right yardstick is a two-year rate. Even so, the one-year figure shows that most men in the core age range did not test that year.
New PSA Guidelines 2026: Who Should Be Screened and When?
Age to Start PSA Screening, by Group
Black men / strong family history | █████████████████████████████████████████████ 45
Single older relative | █████████████████████████████████████████████ 45
Average risk | ██████████████████████████████████████████████████ 50
| Group | Ages | Interval |
|---|---|---|
| Average-risk men | 50-69 | Every 2 years |
| Black men | 45-69 | Every year |
| Strong family history | 45-69 | Every year |
| One relative diagnosed at 65 or older | 45-69 | Every 2 years |
| Men aged 70-74 | 70-74 | Individual decision |
| Men aged 75 and older | 75+ | Not recommended |
Source: American Cancer Society, Updated Prostate Cancer Screening Guideline, November 12, 2026.
ACS now gives a direct recommendation. Average-risk men aged 50 to 69 should have a PSA test every two years, after a clinician explains the benefits and harms. Black men and men with a strong family history should test every year from age 45. A strong history means a father, brother or son diagnosed before 65, or several first-degree relatives diagnosed at any age.
The upper age limits matter as much. For men 70 to 74, ACS says the balance of benefit and harm remains uncertain and calls for individual decisions. It does not recommend screening for men 75 and older, though some very healthy men aged 75 to 79 may want to continue after talking with a clinician. It also advises against screening men 80 and older or men not expected to live another 10 years.
PSA Test Results 2026: What Counts as an Elevated PSA?
PSA Thresholds, ng/mL
Ages 45-69 | ███████████████ 3.0
Ages 70-74 | ████████████████████████████████ 6.5
| Step | Rule |
|---|---|
| Elevated PSA, ages 45-69 | 3.0 ng/mL or higher |
| Elevated PSA, ages 70-74 | 6.5 ng/mL or higher |
| Repeat test | Between 2 weeks and 3 months |
| Confirmed elevated PSA | MRI and/or a validated biomarker |
| Low-risk cancer found | Active surveillance offered first |
| PSA of 2.5 or lower | Screen every 2 years (ABC News summary) |
Source: American Cancer Society, November 12, 2026; ABC News.
An elevated result is not a diagnosis. ACS says men with a PSA of 3.0 ng/mL or higher, aged 45 to 69, should repeat the test within two weeks to three months. The cutoff for men aged 70 to 74 is 6.5 ng/mL. If the repeat is still high, ACS wants an MRI and/or a validated biomarker test before any biopsy.
That added step is a core change. It aims to cut unnecessary biopsies, which can cause bleeding and infection. ACS also says men with low-risk cancer should be offered active surveillance first, meaning close monitoring instead of immediate treatment. ABC News reported that men with a PSA at or below 2.5 can test every two years, while a rising trend matters more than one reading.
ACS vs USPSTF Screening Guidelines 2026: How Do They Differ?
Youngest Starting Age by Group
ACS, high-risk | █████████████████████████████████████████████ 45
ACS, average | ██████████████████████████████████████████████████ 50
USPSTF | ███████████████████████████████████████████████████████ 55
| Item | ACS 2026 | USPSTF 2018 |
|---|---|---|
| Starting age, average risk | 50 | 55 |
| Starting age, high risk | 45 | Not separate |
| Upper age | 69 (70-74 individual) | 69 |
| Men 70 and older | Individual decision to 74 | Recommends against |
| Style | Direct recommendation | Individual decision |
Source: American Cancer Society, CA: A Cancer Journal for Clinicians, 2026; U.S. Preventive Services Task Force.
The two groups agree on the main test. Both use PSA. They differ on timing and tone. The US Preventive Services Task Force, a federal advisory panel, says the decision to be screened for men aged 55 to 69 should be an individual one. It recommends against screening men 70 and older. It has not changed its recommendation since 2018.
ACS goes further. It sets a starting age of 50 for average-risk men and 45 for high-risk men, and it sets intervals. ACS says the evidence has become stronger since its 2010 guideline. CNN reported that one expert thinks high-risk men should start closer to 40. Men should ask their clinician which guideline their practice follows.
Prostate Cancer Statistics 2026: How Common and How Deadly Is It?
5-Year Relative Survival by Stage (1 block = 2%)
Local and regional | ██████████████████████████████████████████████████ over 99%
Distant | ███████████████████ 38%
| Measure | Figure |
|---|---|
| Estimated new cases, 2026 | 333,830 |
| Estimated deaths, 2026 | 36,320 |
| Lifetime risk | About 1 in 8 men |
| Share of new cancers in men | Nearly 1 in 3 |
| Death rate decline since 1993 | 53% |
| 5-year survival, local and regional | Over 99% |
| 5-year survival, distant | 38% |
Source: American Cancer Society, Cancer Facts & Figures 2026; Cancer Statistics 2026; SingleCare summary of ACS data.
Prostate cancer makes up nearly 1 in 3 new cancer diagnoses in American men. It is diagnosed about twice as often as lung cancer, the second-ranking cancer in men. Even so, the death rate has fallen 53% since 1993. Five-year survival tops 99% when the cancer is found locally or regionally.
Stage is what changes the outlook. For cancer that has spread to distant organs, five-year survival drops to 38%. That gap is why screening focuses on finding tumors before they spread. ACS also says it wants to avoid treating slow-growing cancers that may never cause harm, which is why the guideline now adds MRI and active surveillance.
High-Risk Men and Prostate Cancer 2026: Who Needs to Start Earlier?
Black Men vs White Men, 2026 ACS Figures
Higher incidence | ██████████████████████████████████ 67% higher
Mortality | ██████████████████████████████████████████████████ nearly 2x
| High-Risk Group | ACS 2026 Recommendation |
|---|---|
| Black men | Annual PSA from age 45 to 69 |
| Father, brother or son diagnosed before 65 | Annual PSA from age 45 to 69 |
| Several first-degree relatives diagnosed at any age | Annual PSA from age 45 to 69 |
| One first-degree relative diagnosed at 65 or older | PSA every 2 years, ages 45 to 69 |
| Black men’s incidence vs White men | 67% higher |
| Black men’s mortality vs White men | Nearly double |
Source: American Cancer Society, November 12, 2026.
The gap is large. ACS says Black men face a 67% higher incidence and nearly double the mortality of White men. That is why the guideline sets annual testing from age 45 for them. ACS says the aim is to help reduce prostate cancer disparities and ease the disease burden.
Family history counts as well. A father, brother or son diagnosed before age 65 puts a man in the annual group. So do several affected first-degree relatives at any age. A man with a single relative diagnosed at 65 or older follows a lighter schedule of every two years from age 45. A man who is unsure of his family history should ask relatives and tell his clinician.
Prostate Cancer Risk by Age 2026: Which Age Groups Face the Most Risk?
Share of 2022 US Prostate Cancer Cases (1 block = 2%)
Ages 45-54 | ███ 5%
Ages 55-69 | ██████████████████████████ 52%
Ages 70+ | ██████████████████████ 43%
| Measure | Age Group | Figure |
|---|---|---|
| Chance of diagnosis | Birth to 49 | 1 in 480 |
| Chance of diagnosis | 50-64 | 1 in 26 |
| Chance of diagnosis | 65-84 | 1 in 9 |
| Chance of diagnosis | 85 and older | 1 in 30 |
| Share of 2022 cases | 45-54 | 5% |
| Share of 2022 cases | 55-69 | 52% |
| Share of 2022 cases | 70 and older | 43% |
Source: American Cancer Society, Cancer Facts & Figures 2026 (via SingleCare); Centers for Disease Control and Prevention, 2025.
Risk climbs steeply with age. Men under 50 face about 1 in 480. Men aged 50 to 64 face 1 in 26, and men aged 65 to 84 face 1 in 9. The figure for men 85 and older falls to 1 in 30, because few men that age are newly diagnosed. These are secondhand figures from a health publisher citing ACS, so check the original ACS tables before quoting them in print.
The CDC says 52% of 2022 cases occurred in men aged 55 to 69, 43% in men 70 and older, and 5% in men 45 to 54. That split explains why guidelines center on ages 50 to 69. Men aged 40 to 54 are screened far less, with only 12.9% testing in the past year, according to the National Cancer Institute.
PSA Testing Rates in US 2026: How Many Men Actually Get Screened?
Men Tested in Past Year, 2023 (1 block = 2%)
Ages 40-54 | ██████▌ 12.9%
Ages 55-69 | ███████████████████ 38.0%
Ages 70+ | ██████████████████████▌ 45.3%
| Age Group | PSA Test in Past Year, 2023 |
|---|---|
| Ages 40-54 | 12.9% |
| Ages 55-69 | 38.0% |
| Ages 70 and older | 45.3% |
| Men 55-69, ever tested (BRFSS 2023) | 62.7% |
| Distant-stage rise, men under 55 | 2.6% per year |
| Distant-stage rise, men 55-69 | 6.0% per year |
| Distant-stage rise, men 70 and older | 6.2% per year |
Source: National Cancer Institute, Cancer Trends Progress Report; JAMA Network Open, 2026; American Cancer Society, Prostate Cancer Statistics 2025.
Men aged 70 and older had the highest one-year testing rate at 45.3%, even though federal advisers recommend against screening at that age and ACS calls for individual decisions. Men aged 55 to 69, the core group, tested at 38.0%. A 2026 study in JAMA Network Open found that 62.7% of men aged 55 to 69 reported ever having a PSA test. Men with disabilities tested less often.
Advanced disease is rising. Over the past decade, distant-stage diagnoses grew 2.6% per year in men under 55, 6.0% in men 55 to 69, and 6.2% in men 70 and older, according to the ACS 2025 prostate report. Researchers have raised lower screening as one possible factor. That link is an association, not proof of cause.
Prostate Cancer Screening Awareness 2026: What Do Men Know About PSA Tests?
ACS and Harris Poll Survey, August 2024 (1 block = 2%)
Believe rectal exam is first step | ██████████████████████████████ 60%
Hispanic men, same belief | ██████████████████████████████████▌ 69%
Unscreened men 45-59 "too young" | ██████████████████▌ 37%
| Survey Finding | Result |
|---|---|
| Men surveyed (ages 45 and older) | About 1,200 |
| Believed a rectal exam is the first step | 60% |
| Hispanic men with the same belief | 69% |
| Unscreened men aged 45-59 who felt too young | 37% |
| Men aged 55-69 reporting no screening (2024 report) | About two-thirds |
Source: American Cancer Society and Harris Poll survey, August 2024 (reported by HealthDay, September 2024).
The survey is two years old but still useful, because it shows what the new guideline must overcome. About 60% of the 1,200 men surveyed thought a doctor’s rectal exam is the first step in screening. It is not. Screening starts with a PSA blood test. Among Hispanic men the figure rose to 69%. A man who expects an invasive exam may avoid the conversation.
Age beliefs matter too. Among unscreened men aged 45 to 59, 37% said they felt too young to need screening. The 2026 guideline directly challenges that view for Black men and men with a strong family history, who should start at 45. ACS reported in 2024 that about two-thirds of men aged 55 to 69 said they had no screening, so the new schedule targets a large gap.
Prostate Cancer Screening Guideline Timeline 2026: How Did We Get Here?
Recommended Starting Age by Guideline (years)
ACS 2026, high-risk | ██████████████████ 45
ACS 2026, average | ███████████████████████ 50
USPSTF 2018 | ███████████████████████████████ 55
| Year | Guideline Event |
|---|---|
| 2010 | ACS leaves most men to shared decision-making |
| 2018 | USPSTF sets individual decision for men 55-69 |
| 2024 | ACS and Harris Poll survey finds screening myths |
| 2025 | New evidence emerges; USPSTF unchanged |
| November 12, 2026 | ACS issues direct PSA schedule |
Source: American Cancer Society; U.S. Preventive Services Task Force; STAT News.
The 2026 update ends a 16-year gap. ACS had last updated the guideline in 2010, when it told most men to decide with their doctors. The Task Force followed in 2018 with an individual-decision model for men 55 to 69. Between those dates, studies and new tools changed the picture, including better follow-up testing after an elevated PSA.
The new guideline is the first in this timeline to name specific screening ages and intervals for each risk group. ACS reviewed the evidence, commissioned a modeling study, and used a volunteer panel of clinicians, epidemiologists, biostatisticians and patient representatives. It calls the document a living guideline. The Task Force has not announced a change, so differences between the two will persist for now.
Prostate Cancer Screening FAQ 2026
What Are the New Prostate Cancer Screening Guidelines in 2026?
ACS recommends PSA screening every 2 years for average-risk men aged 50 to 69, and every year from age 45 for Black men and men with a strong family history.
When Should Black Men Start PSA Screening in 2026?
At age 45, with annual testing through age 69, according to the November 12, 2026 ACS guideline.
What PSA Level Is Considered Elevated in 2026?
3.0 ng/mL or higher for men aged 45 to 69, and 6.5 ng/mL or higher for men aged 70 to 74.
What Happens After an Elevated PSA Result?
A repeat test within 2 weeks to 3 months. If it stays high, ACS says men should be offered MRI and/or a validated biomarker test before a biopsy decision.
Should Men Over 75 Get Prostate Cancer Screening?
ACS does not recommend screening for men 75 and older. Some very healthy men aged 75 to 79 may want to continue after talking with a clinician.
What Is the USPSTF Prostate Screening Recommendation?
For men 55 to 69, it says the decision should be an individual one. It recommends against screening men 70 and older.
How Many Men Get Prostate Cancer in the US?
An estimated 333,830 men will be diagnosed in 2026, and about 1 in 8 men will be diagnosed in their lifetime.
How Many Men Die of Prostate Cancer Each Year?
An estimated 36,320 men will die of the disease in 2026.
What Is the Survival Rate for Prostate Cancer?
Five-year survival is over 99% for local and regional disease and 38% for distant disease.
Does an Elevated PSA Mean I Have Cancer?
No. ACS says an elevated PSA does not mean a man has prostate cancer. Follow-up testing decides if a biopsy is truly needed.
What Are the Risks of a Prostate Biopsy?
ACS says biopsies can cause complications, including bleeding and infection.
Disclaimer: The data research report we present here is based on information found from various sources. We are not liable for any financial loss, errors, or damages of any kind that may result from the use of the information herein. We acknowledge that though we try to report accurately, we cannot verify the absolute facts of everything that has been represented.
